Medicare Enrolled
Dr. Kenneth Lessans, MD
Urology Physician · Lancaster, PA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Lessans from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Lessans?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Lessans
Dr. Kenneth Lessans is an urology physician in Lancaster, PA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Lessans performed 7,365 Medicare services across 1,899 unique beneficiaries.
Between the years covered by Open Payments, Dr. Lessans received a total of $13,254 from 64 pharmaceutical and/or device companies across 555 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Lessans is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 6% volume in PA
$13,254 industry payments
Medicare Practice Summary
Medicare Utilization ↗7,365
Medicare services
Top 6% in PA for urology physician
1,899
Unique beneficiaries
$18
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~368 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Contrast dye for imaging (iodine-based) A contrast agent containing 300-399 mg/ml of iodine used to enhance imaging studies. It is administered per milliliter to improve the visibility of internal structures. |
2,751 | $0 | $3 |
| BCG treatment for bladder cancer | 2,323 | $2 | $4 |
| Automated urinalysis An automated laboratory test performed on a urine sample to analyze its chemical and physical properties. The procedure uses machinery to detect various substances and cells within the urine. |
491 | $2 | $15 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
440 | $88 | $210 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
245 | $53 | $139 |
| Bladder ultrasound after voiding An ultrasound scan performed after urination to measure the amount of urine remaining in the bladder. |
127 | $8 | $41 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
99 | $38 | $84 |
| Urinalysis with microscopic exam A urine test performed manually that includes examining the sample under a microscope to check for abnormalities. |
94 | $3 | $20 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
84 | $116 | $323 |
| Complete ultrasound of retroperitoneum An ultrasound examination of the structures located behind the abdominal cavity. |
81 | $74 | $316 |
| Bladder instillation of anti-cancer drug A procedure where an anti-cancer medication is introduced directly into the bladder. This method delivers the treatment locally to the bladder tissue. |
71 | $65 | $553 |
| Simple insertion of temporary bladder tube A procedure to place a temporary tube into the bladder. This allows for the drainage of urine from the bladder. |
55 | $43 | $249 |
| Non-needle muscle activity measurement of bladder and bowel openings This procedure measures and records the electrical activity of muscles at the bladder and bowel openings without using needles. |
46 | $31 | $559 |
| Functional capacity test, per 15 minutes A test or measurement to assess functional capacity. The service is billed for each 15-minute increment. |
45 | $24 | $65 |
| Cystourethroscopy A diagnostic exam of the bladder and urethra using an endoscope to visually inspect the urinary tract. |
41 | $174 | $585 |
| Complex urodynamic pressure flow study A test that measures the pressure of urine flow in the bladder during voiding to evaluate how well the bladder and urethra are functioning. |
31 | $263 | $594 |
| CT scan of abdomen and pelvis with contrast A CT scan of the abdomen and pelvis using contrast dye before and after administration to visualize internal structures. |
30 | $175 | $800 |
| Initial hospital admission, low complexity Initial hospital inpatient or observation care for a new patient involving straightforward or low-level medical decision making, with at least 40 minutes total time on the date of the encounter. |
29 | $64 | $201 |
| Abdominal device insertion with pressure and urine flow study A procedure involving the placement of a device into the abdomen, accompanied by a study to measure pressure and urine flow rate. |
28 | $145 | $419 |
| Cystoscopy with chemical ablation of bladder A procedure where a camera is used to examine the bladder and a chemical agent is applied to destroy abnormal tissue. |
28 | $128 | $588 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
28 | $96 | $281 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
26 | $17 | $46 |
| Transrectal ultrasound of the pelvis An ultrasound imaging procedure where a probe is inserted into the rectum to visualize pelvic structures. |
22 | $98 | $327 |
| Electronic assessment of bladder emptying A test that uses electronic monitoring to evaluate how well the bladder empties urine. |
21 | $6 | $209 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
21 | $22 | $115 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
19 | $34 | $84 |
| CT scan of abdomen and pelvis, without contrast A computed tomography scan that creates detailed images of the abdominal and pelvic organs. The procedure is performed without the use of intravenous contrast dye. |
17 | $75 | $475 |
| Bladder irrigation and/or instillation This procedure involves flushing the bladder with fluid to clear it or introducing medication directly into the bladder. |
16 | $47 | $476 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
15 | $68 | $210 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
15 | $91 | $227 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
14 | $8 | $15 |
| Limited retroperitoneal ultrasound A focused ultrasound exam of the area behind the abdominal cavity to evaluate specific structures. |
12 | $45 | $240 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.4% high complexity
41.6% medium
58.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$13,254
Total received (2018-2024)
Avg $1,893/year across 7 years
Top 11% in PA for urology physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
64
Companies
555
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$10,756 (81.2%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$2,413 (18.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$85 (0.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$5,008
2023
$2,238
2022
$2,233
2021
$1,548
2020
$337
2019
$973
2018
$917
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$2,413
Dendreon Pharmaceuticals LLC
$685
Merck Sharp & Dohme LLC
$346
Sumitomo Pharma America, Inc.
$257
AstraZeneca Pharmaceuticals LP
$226
Astellas Pharma US Inc
$183
ABBVIE INC.
$181
PROCEPT BioRobotics Corporation
$147
Ferring Pharmaceuticals Inc.
$76
Axonics, Inc.
$68
Bayer Healthcare Pharmaceuticals Inc.
$57
Telix Pharmaceuticals
$42
IMMUNITYBIO, INC.
$40
Novartis Pharmaceuticals Corporation
$38
Myriad Genetic Laboratories, Inc.
$35
Baxter Healthcare
$34
UROGEN PHARMA, INC.
$32
PFIZER INC.
$30
PROGENICS PHARMACEUTICALS, INC.
$29
BLUEWIND MEDICAL
$19
Provepharm Inc.
$19
Teleflex LLC
$18
Verity Pharmaceuticals Inc.
$17
COLOPLAST CORP
$15
Top 3 companies account for 68.8% of 2024 payments
All-time payments by company (2018-2024) ›
Janssen Biotech, Inc.
$2,554
Dendreon Pharmaceuticals LLC
$1,593
AstraZeneca Pharmaceuticals LP
$1,204
Astellas Pharma US Inc
$1,114
PFIZER INC.
$682
Merck Sharp & Dohme LLC
$625
Sumitomo Pharma America, Inc.
$520
Axonics, Inc.
$431
UROVANT SCIENCES INC
$429
Myriad Genetic Laboratories, Inc.
$296
Bayer HealthCare Pharmaceuticals Inc.
$288
PROCEPT BioRobotics Corporation
$267
Ferring Pharmaceuticals Inc.
$252
ABBVIE INC.
$243
Avadel Specialty Pharmaceuticals, LLC
$230
Coloplast Corp
$218
Allergan, Inc.
$144
Medtronic, Inc.
$133
Merck Sharp & Dohme Corporation
$131
Teleflex LLC
$124
Boston Scientific Corporation
$110
Verity Pharmaceuticals Inc.
$100
UroGen Pharma, Inc.
$97
NeoTract Inc.
$91
Janssen Products, LP
$85
Novartis Pharmaceuticals Corporation
$82
Bayer Healthcare Pharmaceuticals Inc.
$75
Baxter Healthcare
$68
Blue Earth Diagnostics Limited
$65
Myovant Sciences Inc.
$65
UROGEN PHARMA, INC.
$61
Travere Therapeutics, Inc.
$52
Foundation Medicine, Inc.
$47
Axonics Modulation Technologies, Inc.
$45
Retrophin, Inc.
$43
Telix Pharmaceuticals
$42
TOLMAR Pharmaceuticals, Inc.
$42
ROCHESTER MEDICAL CORPORATION
$41
E.R. Squibb & Sons, L.L.C.
$40
IMMUNITYBIO, INC.
$40
TherapeuticsMD, Inc.
$38
ACCORD HEALTHCARE, INC.
$36
Sanara MedTech Inc.
$35
Caldera Medical, Inc
$30
Allergan Inc.
$30
PROGENICS PHARMACEUTICALS, INC.
$29
Tolmar, Inc.
$29
Antares Pharma, Inc.
$22
BLUEWIND MEDICAL
$19
Provepharm Inc.
$19
Photocure Inc
$19
ABC Home Medical Supply, Inc.
$18
C. R. Bard, Inc. & Subsidiaries
$17
Laborie Medical Technologies Corp.
$16
Progenics Pharmaceuticals, Inc.
$15
COLOPLAST CORP
$15
KARL STORZ Endoscopy-America
$15
Endo Pharmaceuticals Inc.
$13
Hollister Incorporated
$13
Olympus America Inc.
$13
Alnylam Pharmaceuticals Inc.
$13
Amniox Medical, Inc.
$13
Prometheus Laboratories Inc.
$11
Ethicon US, LLC
$11
Top 3 companies account for 40.4% of all-time payments
Associated products mentioned in payments ›
(815) Thiola · ADSTILADRIN · ANKTIVA · ANNOVERA · AQUABEAM ROBOTIC SYSTEM · AQUABEAM SYSTEM · AUTOCLAV · Altis · Axonics · Axonics r-SNM System · Axumin · BLUDIGO · BOTOX · BOTOX THERAPEUTIC · Balversa · Bard Urinary Drainage Bag · Bulkamid · CAMCEVI · CellerateRx · Cysview · Desara · ECHELON FLEX Stapler · ELIGARD · ERLEADA · Erleada · FIRMAGON · FOUNDATIONONE · FOUNDATIONONE HEME · Flexiva · GEMTESA · HOPKINS II · ILLUCCIX · IMFINZI · IMVEXXY · INTERSTIM · JELMYTO · KEYTRUDA · LITHOVUE · LYNPARZA · MYRBETRIQ · Myrbetriq · NEOX · NOCDURNA · New Image · Noctiva · Nubeqa · OPDIVO · ORGOVYX · OXLUMO · PERCLOT · PLUVICTO · PREMARIN · PROLARIS · PROVENGE · PYLARIFY · Porges Coloplast · Prolaris · Proleukin · REVI · SenSura Mio · SpeediCath · TELESCOPE · TISSEEL · TOVIAZ · Thiola · Trelstar · UROLIFT · UroLift · UroLift System · VESICARE · Veozah · XIAFLEX · XTANDI · XYOSTED · Xofigo · Xtandi · ZYTIGA · iTIND System
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (81%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Lessans is a mixed practice specialist, with above-average Medicare volume (top 6% in PA), with low-engagement industry engagement in the top 11% of PA peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Lessans experienced with contrast dye for imaging (iodine-based)?
Based on Medicare claims data, Dr. Lessans performed 2,751 contrast dye for imaging (iodine-based) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Lessans receive payments from pharmaceutical companies?
Yes. Dr. Lessans received a total of $13,254 from 64 companies across 555 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Lessans's costs compare to other urology physicians in Lancaster?
Dr. Lessans's average Medicare payment per service is $18. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Lessans) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Urology Physicians in Lancaster
Browse urology physicians in Lancaster ranked by procedure volume and transparency data.
Highest volume
Top Urology Physicians in PA
Urology physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Urology Physicians in PA
Which PA urology physicians receive the most from drug and device companies.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
Dendreon Pharmaceuticals LLC Payments to Doctors
See all physicians who received payments from Dendreon Pharmaceuticals LLC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology